| Literature DB >> 19735579 |
Hongbo Zhao1, Qishan Wang, Chunyan Bai, Kan He, Yuchun Pan.
Abstract
BACKGROUND: Endometriosis is an enigmatic disease. Gene expression profiling of endometriosis has been used in several studies, but few studies went further to classify subtypes of endometriosis based on expression patterns and to identify possible pathways involved in endometriosis. Some of the observed pathways are more inconsistent between the studies, and these candidate pathways presumably only represent a fraction of the pathways involved in endometriosis.Entities:
Mesh:
Year: 2009 PMID: 19735579 PMCID: PMC2752458 DOI: 10.1186/1477-7827-7-94
Source DB: PubMed Journal: Reprod Biol Endocrinol ISSN: 1477-7827 Impact factor: 5.211
Characteristics of datasets included in the studies.
| Sha [ | U133 PLUS 2.0 | GSE7846 | unpaired, HEECS | ovarian | 54K | 5 | 5 |
| Burney [ | U133 PLUS 2.0 | GSE6364 | unpaired, tissues | Ovarian, peritoneal, | 54K | 21 | 16 |
| Eyster [ | CodeLink | GSE5108 | paired, tissues | Ovarian, peritoneal | 55K | 6/5 | 6/5 |
| Hever [ | U133 PLUS 2.0 | GSE7305 | paired, tissues | ovarian | 54K | 10 | 10 |
| Roth | U133 PLUS 2.0 | GSE7307 | unpaired, tissues | ovarian | 54K | 18 | 23 |
| Hull [ | U133A | GSE11691 | paired, tissues | peritoneal | 22K | 9 | 9 |
paried: compare eutopic endometrium to ectopic endometrium from the same patients with entire endometrial tissue.
unparied: compare eutopic endometrium from women with endometriosis to eutopic endometrium from women without endometriosis.
HEECS: human endometrial endothelial cells samples.
Summary of each data set used in the re-analysis and the number of differentially expressed pathways.
| Ovarian Data Sets | ||||||
| Eyster | 6 | 6 | 3105 | 171 | 24 | 31 |
| Hever | 10 | 10 | 1930 | 139 | 56 | 59 |
| Roth | 18 | 23 | 2575 | 154 | 36 | 44 |
| Peritoneal Data Sets | ||||||
| Eyster | 5 | 5 | 3084 | 171 | 57 | 11 |
| Hull | 9 | 9 | 1255 | 113 | 29 | 7 |
| Uterine cycle Data Sets | ||||||
| Burney_Pro | 6 | 5 | 1900 | 138 | 4 | 3 |
| Burney_ES | 6 | 3 | 1471 | 122 | 12 | 21 |
| Burney_MS | 9 | 8 | 952 | 93 | 0 | 22 |
| Human endometrial endothelial cells Data Set | ||||||
| Sha | 5 | 5 | 2324 | 153 | 44 | 1 |
Pro, Proliferative; ES, early secretory; MS, midsecretory Proliferative
Common pathway categories identified by GSEA of the 3 ovarian endometriosis datasets
| Up-regulation | ||
| PPAR signaling pathway | Endocrine System | 26 |
| Cytokine-cytokine receptor interaction | Signaling Molecules and Interaction | 84 |
| Cell adhesion molecules (CAMs) | Signaling Molecules and Interaction | 68 |
| Complement and coagulation cascades | Immune System | 32 |
| Toll-like receptor signaling pathway | Immune System | 37 |
| Hematopoietic cell lineage | Immune System | 36 |
| Asthma | Immune Disorders | 12 |
| Autoimmune thyroid disease | Immune Disorders | 16 |
| Systemic lupus erythematosus | Immune Disorders | 29 |
| Allograft rejection | Immune Disorders | 16 |
| Graft-versus-host disease | Immune Disorders | 17 |
| Arachidonic acid metabolism | Lipid Metabolism | 19 |
| Metabolism of xenobiotics by cytochrome P450 | Xenobiotics Biodegradation and Metabolism | 19 |
| Drug metabolism - cytochrome P450 | Xenobiotics Biodegradation and Metabolism | 20 |
| Type I diabetes mellitus | Metabolic Disorders | 19 |
| Olfactory transduction | Sensory System | 4 |
| Down-regulation | ||
| Fatty acid metabolism | Lipid Metabolism | 21 |
| Androgen and estrogen metabolism | Lipid Metabolism | 5 |
| Sphingolipid metabolism | Lipid Metabolism | 18 |
| Oxidative phosphorylation | Energy Metabolism | 44 |
| Citrate cycle (TCA cycle) | Carbohydrate Metabolism | 13 |
| Butanoate metabolism | Carbohydrate Metabolism | 12 |
| Pyrimidine metabolism | Nucleotide Metabolism | 36 |
| Glycosylphosphatidylinositol(GPI)-anchor biosynthesis | Glycan Biosynthesis and Metabolism | 10 |
| Lysine degradation | Amino Acid Metabolism | 19 |
| Folate biosynthesis | Metabolism of Cofactors and Vitamins | 10 |
| DNA polymerase | Replication and Repair | 22 |
| Base excision repair | Replication and Repair | 16 |
| Nucleotide excision repair | Replication and Repair | 19 |
| Mismatch repair | Replication and Repair | 13 |
| Homologous recombination | Replication and Repair | 10 |
| Cell cycle | Cell Growth and Death | 57 |
| Thyroid cancer | Cancers | 15 |
| Proteasome | Folding, Sorting and Degradation | 13 |
| Ubiquitin mediated proteolysis | Folding, Sorting and Degradation | 50 |
Genes: Number of common genes included in the pathway.
Figure 1Significant pathways identified and overlap between the 3 ovarian endometriosis data sets. For each data set, GSEA implanted to generate p-values for each pathway and using a permutation test with 1000 times, obtained the significant pathways with p-value cut-off of ≤ 0.05. (a) GSEA detected 24 (Eyster data set), 56 (Hever data set) and 36 (Roth data set) up-regulated pathways and 16 are common. (b) GSEA detected 31 (Eyster data set), 59 (Hever data set) and 44(Roth data set) down-regulated pathways and 19 are common.
Common pathway categories identified by GSEA of the 2 peritoneal endometriosis datasets
| Up-regulation | ||
| Cell Communication | Cell Communication | 42 |
| Focal adhesion | Cell Communication | 91 |
| Regulation of actin cytoskeleton | Cell Motility | 61 |
| PPAR signaling pathway | Endocrine System | 19 |
| Calcium signaling pathway | Signal Transduction | 41 |
| VEGF signaling pathway | Signal Transduction | 25 |
| Cytokine-cytokine receptor interaction | Signaling Molecules and Interaction | 58 |
| Neuroactive ligand-receptor interactio | Signaling Molecules and Interaction | 20 |
| ECM-receptor interaction | Signaling Molecules and Interaction | 46 |
| Cell adhesion molecules (CAMs) | Signaling Molecules and Interaction | 49 |
| Complement and coagulation cascades | Immune System | 29 |
| Hematopoietic cell lineage | Immune System | 29 |
| Leukocyte transendothelial migration | Immune System | 44 |
| Asthma | Immune Disorders | 7 |
| Autoimmune thyroid disease | Immune Disorders | 12 |
| Systemic lupus erythematosus | Immune Disorders | 20 |
| Allograft rejection | Immune Disorders | 12 |
| Graft-versus-host disease | Immune Disorders | 15 |
| Arachidonic acid metabolism | Lipid Metabolism | 16 |
| Type I diabetes mellitus | Metabolic Disorders | 15 |
| Pancreatic cancer | Cancers | 24 |
| Glioma | Cancers | 21 |
| Down-regulation | ||
| Sphingolipid metabolism | Lipid Metabolism | 13 |
Genes: Number of common genes included in the pathway.
Figure 2Significant pathways identified and overlap between the 2 peritoneal endometriosis data sets. For each data set, GSEA implanted to generate p-values for each pathway and using a permutation test with 1000 times, obtained the significant pathways with p-value cut-off of ≤ 0.05. (a) GSEA detected 57 (Eyster data set) and 29 (Hull data set) up-regulated pathways and 22 are common. (b) GSEA detected 11 (Eyster data set) and 7 (Hull data set) down-regulated pathways and 1 is common.
Figure 3Significant pathways identified and overlap between the phases of uterine cycle. For each phase, GSEA implanted to generate p-values for each pathway and using a permutation test with 1000 times, obtained the significant pathways with p-value cut-off of ≤ 0.05. (a) GSEA detected 4 (Proliferative phase), 12 (Early secretory phase) and 0 (Mid secretory phase) up-regulated pathways and no overlap. (a) GSEA detected 3 (Proliferative phase), 21 (Early secretory phase) and 22 (Mid secretory phase) down-regulated pathways and the overlap is very low.